Economic Evaluation of Roxalrestat versus Recombinant Human Erythro-poietin-beta in the Treatment of Non-dialysis Renal Anemia
OBJECTIVE To provide reference for optimizing drug treatment plans in clinical practice,the eco-nomic benefits of two drug-therapies for treating renal anemia in non-dialysis elderly patients were analyzed and com-pared from the perspective of medical institutions.METHODS The medical records of non-dialysis elderly patients with renal anemia that were treated using roxadustat capsules and recombinant human eiythropoietin-β were reviewed in a certain hospital in Fujian Province from July 2020 to August 2023.The cost and effectiveness of two treatment options were analyzed and sensitivity analysis of influencing factors were conducted based on the constructed Markov model.RESULTS The treatment cost of the roxadustat group and the recombinant human erythropoietin-β group were 58432.20 yuan and 65712.91 yuan,with utility of 1.3723 QALYS and 1.5521 QALYS,and cost effectiveness ratio of 42579.76 yuan/QALYS and 42338.06 yuan/QALYS,respectively;The incremental costeffectiveness ratio was 40493.38 yuan/QALYS,which was less than the willingness-to-pay threshold;Sensitivity analysis showed that the results of this study were reliable.CONCLUSION To compare with Recombinant human erythropoietin-β,The treatment of renal anemia in non-dialysis elderly patients by using roxadustat capsules was economically more advan-tageous in the current economic climate.
RoxadustatRecombinant human erythropoietin-βCost utilityMarkov modelNon-dialytic renal anemia
NETL
NSTL
万方数据
